GGHC
ATXS

Gilder Gagnon Howe & Co’s Astria Therapeutics ATXS Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-374
Closed -$81K – 279
2016
Q4 		$81K Hold
374
– – ﹤0.01% 240
2016
Q3 		$138K Buy
+374
New +$98.5K ﹤0.01% 237

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Gilder Gagnon Howe & Co's ATXS Position: Q1 2017 in Review

Gilder Gagnon Howe & Co sold out of Astria Therapeutics (ATXS) in Q1 2017, closing a stake of 374 shares — an estimated $81K sold.

Gilder Gagnon Howe & Co first reported a position in ATXS in Q3 2016 and held it in 2 quarters. The position peaked at $138K in Q3 2016. 23 funds tracked by Wall St. Rank hold ATXS as of Q1 2017.

  • Gilder Gagnon Howe & Co reported no remaining Astria Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 374 Astria Therapeutics shares in Q1 2017, an estimated $81K.
  • Gilder Gagnon Howe & Co first reported a position in Astria Therapeutics in Q3 2016 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Astria Therapeutics position peaked at $138K in Q3 2016.
  • 23 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2017.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2017, filed 11 May 2017.